Company Filing History:
Years Active: 2022-2025
Title: Innovator Jing Ting Christine Yuan: Pioneering Immunomodulatory Research
Introduction
Jing Ting Christine Yuan, based in Brookline, MA, is a prominent inventor known for his significant contributions to immunomodulatory compounds and small molecule degraders. With a total of six patents to his name, Yuan's work is influencing the landscape of pharmaceutical compositions and treatments for diseases associated with aberrant protein activity.
Latest Patents
Among his noteworthy patents, the latest include innovations surrounding immunomodulatory compounds. These compounds and the pharmaceutical compositions derived from them are designed to treat diseases and disorders characterized by aberrant protein activity, specifically targeting cereblon. Another recent patent involves the development of small molecule degraders of Helios, relating to IKZF2 (Helios), which similarly addresses conditions mediated by faulty protein activity. These inventions hold promise for advancing therapeutic strategies in modern medicine.
Career Highlights
Yuan's career is highlighted by his association with the Dana-Farber Cancer Institute, Inc., a leading research institution dedicated to cancer treatment and prevention. His focus on innovative therapeutic approaches has positioned him as a key player in the field of cancer research, underlining his commitment to addressing critical health challenges.
Collaborations
Collaboration is essential in Yuan's research endeavors. He has worked closely with esteemed colleagues such as Nathanael Schiander Gray and Tinghu Zhang, leveraging their expertise to enhance the efficacy and reach of his innovations. These partnerships exemplify the collaborative spirit in the scientific community, fostering the development of breakthrough treatments.
Conclusion
Jing Ting Christine Yuan's contributions to immunomodulatory research and the development of small molecule degraders are paving the way for innovative treatment options. His work at the Dana-Farber Cancer Institute, combined with valuable collaborations, reflects his dedication to addressing critical medical needs through innovation. With a robust portfolio of patents, Yuan continues to be a significant figure in advancing modern therapeutics.